BTIG Maintains Buy on Haemonetics, Raises Price Target to $130
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $110 to $130.
BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $110 to $130.